awmsg logo



ibrutinib (Imbruvica®)


Reference No. 2215

Publication date:
18/11/2015


Appraisal information

ibrutinib (Imbruvica®) 140 mg hard capsule


Company: Janssen-Cilag Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Superseded
Advice No: Not available
Ratification by Welsh Government: 17/11/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA491) NICE GUIDANCE ISSUED NOVEMBER 2017 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)
Statement of Advice (SOA)
Download